Therapeutic drug monitoring for caffeine in preterm neonates: An unnecessary exercise?

Pediatrics

Volumn 119, Issue 5, 2007, Pages 936-940

  Natarajan, Girija ^a   Botica, Mirjana Lulic ^b   Thomas, Ronald ^a   Aranda, Jacob V ^a  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b HUTZEL HOSPITAL   (United States)

Author keywords

Apnea; Caffeine; Methylxanthine; Therapeutic drug monitoring

Indexed keywords

CAFFEINE CITRATE; CREATININE;

APNEA; ARTICLE; BIRTH WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; GESTATIONAL AGE; HUMAN; KIDNEY FUNCTION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; NEWBORN; PREMATURITY; PRIORITY JOURNAL; UREA NITROGEN BLOOD LEVEL;

APNEA; CAFFEINE; CITRATES; DRUG MONITORING; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE;

EID: 34248192297     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2006-2986     Document Type: Article

References (17)

1. Erenberg A, Leff RD, Haack DG, Mosdell KW, Hicks GM, Wynne BA. Caffeine citrate for the treatment of apnea of prematurity: a double-blind placebo controlled study. Pharmacotherapy. 2000;20:644-652
2. Henderson-Smart DJ, Steer P. Methylxanthine treatment for apnea in preterm infants. Cochrane Database Syst Rev. 2001;(3):CD000140
3. Schmidt B, Roberts RS, Davis P, et al. Caffeine for apnea of prematurity trial group: Caffeine therapy for apnea of prematurity. N Engl J Med. 2006;354:2112-2221
4. Young TE, Mangum B. Caffeine citrate. In: Young TE, Mangum B, eds. Neofax. Raleigh, NC: Acorn Publishers, Inc; 2006:202-203
5. Steer P, Flenady V, Shearman A, et al. High-dose caffeine citrate for extubation of preterm infants: a randomized controlled trial. Arch Dis Child Fetal Neonatal Ed. 2004;89:F499-F503
6. Aranda JV, Cook CE, Gorman W, et al. Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. J Pediatr. 1979;94:663-668
7. Aranda JV, Collinge JM, Zinman R, Watters G. Maturation of caffeine elimination in infancy. Arch Dis Child. 1979;54:946-949
8. Le Guennec JC, Billon B, Pare C. Maturational changes of caffeine concentrations and disposition in infancy during maintenance therapy for apnea of prematurity: influence of gestational age, hepatic disease and breast feeding. Pediatrics. 1985;76:834-840
9. Gorodischer R, Karplus M. Pharmacokinetic aspects of caffeine in premature infants with apnea. Eur J Clin Pharmacol. 1982;22:47-52
10. Pesce AJ, Rakhkin M, Kotagal U. Standards of laboratory practice: theophylline and caffeine monitoring. Clin Chem. 1998;44:1124-1128
11. Falcao AC, Fernandez de Gatta MM, Delgado Iribarnegaray MF, et al. Population pharmacokinetics of caffeine in premature neonates. Eur J Clin Pharmacol. 1997;52:211-217
12. de Wildt SN, Kerkvliet KT, Wezenberg MG, et al. Use of saliva in therapeutic drug monitoring of caffeine in preterm infants. Ther Drug Monit. 2001;23:250-254
13. Lee TC, Charles B, Steer P, Flenady VJ, Debuse N. Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity. Clin Pharmacol Ther. 1997;61:628-640
14. Lee HS, Khoo YM, Chirino-Barcelo Y, Tan KL, Ong D. Caffeine in apnoeic Asian neonates: a sparse data analysis. Br J Clin Pharmacol. 2002;54:31-37
15. Thomson AH, Kerr S, Wright S. Population pharmacokinetics of caffeine in neonates and young infants. Ther Drug Monit. 1996;18:245-253
16. Scanlon JEM, Chin KC, Morgan MEI, Durbin GM, Hale KA, Brown SS. Caffeine or theophylline for neonatal apnoea. Arch Dis Child. 1992;67:425-458
17. Turmen T, Davis J, Aranda JV. Relationship of dose and plasma concentrations of caffeine and ventilation in neonatal apnea. Semin Perinatol. 1981;5326-331: